MS Sequencing: Part 5 – Strategies for optimizing response

 

Comment by Dr. Jiwon Oh
NeuroSens survey on sequencing – Part 5

Most RRMS patients begin their treatment journey with a platform therapy, either an injectable or a first-line oral (teriflunomide or dimethyl fumarate in Canada) (see Part 2 of this series). Many will remain on the platform long after the train has pulled out. Only a minority will have their DMT regimen optimized, even when it is recognized that the current treatment has failed (see Part 4 of this series).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page